These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 8855819)

  • 61. Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia.
    Omura-Minamisawa M; Diccianni MB; Batova A; Chang RC; Bridgeman LJ; Yu J; Pullen J; Bowman WP; Yu AL
    Clin Cancer Res; 2000 Apr; 6(4):1219-28. PubMed ID: 10778944
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors.
    Kovar H; Jug G; Aryee DN; Zoubek A; Ambros P; Gruber B; Windhager R; Gadner H
    Oncogene; 1997 Oct; 15(18):2225-32. PubMed ID: 9393981
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc.
    Haviernik P; Schmidt M; Hu X; Wolff L
    Oncogene; 2003 Mar; 22(11):1600-10. PubMed ID: 12642863
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas.
    Saxena A; Robertson JT; Ali IU
    Oncogene; 1996 Aug; 13(3):661-4. PubMed ID: 8760309
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
    Raffel C; Ueki K; Harsh GR; Louis DN
    Neurosurgery; 1995 May; 36(5):971-4; discussion 974-5. PubMed ID: 7791990
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas.
    Gombart AF; Morosetti R; Miller CW; Said JW; Koeffler HP
    Blood; 1995 Aug; 86(4):1534-9. PubMed ID: 7632961
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Frequent hypermethylation of p16 and p15 genes in multiple myeloma.
    Ng MH; Chung YF; Lo KW; Wickham NW; Lee JC; Huang DP
    Blood; 1997 Apr; 89(7):2500-6. PubMed ID: 9116295
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome.
    Scarisbrick JJ; Woolford AJ; Calonje E; Photiou A; Ferreira S; Orchard G; Russell-Jones R; Whittaker SJ
    J Invest Dermatol; 2002 Mar; 118(3):493-9. PubMed ID: 11874489
    [TBL] [Abstract][Full Text] [Related]  

  • 69. p16 gene homozygous deletions in acute lymphoblastic leukemia.
    Quesnel B; Preudhomme C; Philippe N; Vanrumbeke M; Dervite I; Lai JL; Bauters F; Wattel E; Fenaux P
    Blood; 1995 Feb; 85(3):657-63. PubMed ID: 7833469
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors.
    Sato K; Schäuble B; Kleihues P; Ohgaki H
    Int J Cancer; 1996 May; 66(3):305-8. PubMed ID: 8621248
    [TBL] [Abstract][Full Text] [Related]  

  • 71. p16ink4a gene and hematological malignancies.
    Quesnel B; Preudhomme C; Fenaux P
    Leuk Lymphoma; 1996 Jun; 22(1-2):11-24. PubMed ID: 8724524
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia.
    Cayuela JM; Madani A; Sanhes L; Stern MH; Sigaux F
    Blood; 1996 Mar; 87(6):2180-6. PubMed ID: 8630377
    [TBL] [Abstract][Full Text] [Related]  

  • 73. p16 is a major inactivation target in hepatocellular carcinoma.
    Jin M; Piao Z; Kim NG; Park C; Shin EC; Park JH; Jung HJ; Kim CG; Kim H
    Cancer; 2000 Jul; 89(1):60-8. PubMed ID: 10897001
    [TBL] [Abstract][Full Text] [Related]  

  • 74. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
    Williamson MP; Elder PA; Shaw ME; Devlin J; Knowles MA
    Hum Mol Genet; 1995 Sep; 4(9):1569-77. PubMed ID: 8541841
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.
    Suzuki H; Zhou X; Yin J; Lei J; Jiang HY; Suzuki Y; Chan T; Hannon GJ; Mergner WJ; Abraham JM
    Hum Mol Genet; 1995 Oct; 4(10):1883-7. PubMed ID: 8595411
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Alterations of p16INK4A and p15INK4B genes in gastric carcinomas.
    Lee YY; Kang SH; Seo JY; Jung CW; Lee KU; Choe KJ; Kim BK; Kim NK; Koeffler HP; Bang YJ
    Cancer; 1997 Nov; 80(10):1889-96. PubMed ID: 9366289
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients.
    Bassi CL; Martelli L; Cipolotti R; Scrideli CA; Defávery R; Tone LG
    Braz J Med Biol Res; 2004 Nov; 37(11):1683-7. PubMed ID: 15517085
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma.
    Matsumura Y; Nishigori C; Yagi T; Imamura S; Takebe H
    Arch Dermatol Res; 1998 Apr; 290(4):175-80. PubMed ID: 9617435
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.
    Hayette S; Thomas X; Bertrand Y; Tigaud I; Callanan M; Thiebaut A; Charrin C; Archimbaud E; Magaud JP; Rimokh R
    Leukemia; 1997 Oct; 11(10):1696-9. PubMed ID: 9324291
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mutational analysis of the p15 and p16 genes in acute leukaemias.
    Sill H; Aguiar RC; Schmidt H; Hochhaus A; Goldman JM; Cross NC
    Br J Haematol; 1996 Mar; 92(3):681-3. PubMed ID: 8616035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.